2023-507526-17-00招募中2 期
Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Bayer AG
- 入组人数
- 1
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Therapeutic Area Head
Scientific
Bayer AG
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.Pulmonary HypertensionNCT00855465Bayer262
已完成
3 期
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)Pulmonary HypertensionNCT00810693Bayer445
进行中（未招募）
1 期
A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid ArthritisEstudio fase 1b/II de dosis múltiples, para evaluar seguridad y farmacocinética/farmacodinámica de LY2189102 en pacientes con artritis reumatoide.Artritis ReumatoideEUCTR2005-002660-29-ESilly S.A.135
进行中（未招募）
不适用
A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid ArthritisRheumatoid ArthritisEUCTR2005-002660-29-HUEli Lilly and Company Limited135
进行中（未招募）
1 期
Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitorsEUCTR2017-003324-67-ITBAYER HEALTHCARE AG24